Supernus Pharmaceuticals EBITDA 2011-2024 | SUPN
Supernus Pharmaceuticals ebitda from 2011 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Supernus Pharmaceuticals Annual EBITDA
(Millions of US $) |
| 2023 |
$80 |
| 2022 |
$137 |
| 2021 |
$137 |
| 2020 |
$206 |
| 2019 |
$167 |
| 2018 |
$162 |
| 2017 |
$107 |
| 2016 |
$57 |
| 2015 |
$23 |
| 2014 |
$-2 |
| 2013 |
$-58 |
| 2012 |
$-41 |
| 2011 |
$-37 |
| 2010 |
$-39 |
Supernus Pharmaceuticals Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$43 |
| 2024-03-31 |
$19 |
| 2023-12-31 |
$21 |
| 2023-09-30 |
$30 |
| 2023-06-30 |
$3 |
| 2023-03-31 |
$25 |
| 2022-12-31 |
$56 |
| 2022-09-30 |
$23 |
| 2022-06-30 |
$35 |
| 2022-03-31 |
$23 |
| 2021-12-31 |
$25 |
| 2021-09-30 |
$45 |
| 2021-06-30 |
$44 |
| 2021-03-31 |
$22 |
| 2020-12-31 |
$53 |
| 2020-09-30 |
$64 |
| 2020-06-30 |
$54 |
| 2020-03-31 |
$35 |
| 2019-12-31 |
$45 |
| 2019-09-30 |
$44 |
| 2019-06-30 |
$48 |
| 2019-03-31 |
$30 |
| 2018-12-31 |
$46 |
| 2018-09-30 |
$43 |
| 2018-06-30 |
$39 |
| 2018-03-31 |
$34 |
| 2017-12-31 |
$36 |
| 2017-09-30 |
$27 |
| 2017-06-30 |
$27 |
| 2017-03-31 |
$17 |
| 2016-12-31 |
$17 |
| 2016-09-30 |
$21 |
| 2016-06-30 |
$12 |
| 2016-03-31 |
$7 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$6 |
| 2015-06-30 |
$4 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$6 |
| 2014-09-30 |
$0 |
| 2014-06-30 |
$5 |
| 2014-03-31 |
$-13 |
| 2013-12-31 |
$-10 |
| 2013-09-30 |
$-16 |
| 2013-06-30 |
$-15 |
| 2013-03-31 |
$-18 |
| 2012-12-31 |
$-12 |
| 2012-09-30 |
$-12 |
| 2012-06-30 |
$-9 |
| 2012-03-31 |
$-8 |
| 2011-12-31 |
$-10 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$-8 |
| 2011-03-31 |
$-9 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.872B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
